Title: Antibodies Market Analysis
1Antibodies Market
2The global antibodies market is estimated to
account for US 147,385.1 Mn in terms of value
and is expected to reach US 384,011.6 Mn by the
end of 2027. Antibody, also called
as immunoglobulin, is a protein produced by
plasma cells in response to specific antigens.
These Antibodies can be used as therapeutic as
well as diagnostic purposes for several
indications, including cancers, autoimmune
disorders, inflammatory infectious diseases and
others.
3- The adoption of antibody-based drugs for the
treatment of cancer has significantly
increased. Monoclonal antibody therapeutics offer
high specificity, activity, favorable
pharmacokinetics, and standardized manufacturing
processes. - Moreover, antibodies can increase immune response
against cancer cells through complement-dependent
cytotoxicity or antibody dependent cellular
cytotoxicity. - The use of antibodies as a diagnostic reagents
for the identification of disease markers or
proteins based on immunoassays has decreased. - This is attributed to increasing accuracy of
molecular diagnostic tools.
4- For more details, visit-https//cmiblogdailydose.b
logspot.com/2022/07/antibodies-component-of-immune
e-system.html - Global Antibodies Market Competitive Landscape
- Novartis AG, F. Hoffmann-La Roche Ltd., Johnson
Johnson Services, Inc., Takeda Pharmaceutical
Company Limited, Amgen Inc., Biogen Inc.,
Bristol-Myers Squibb Company, AbbVie Inc.,
Sanofi, Eli Lilly and Co., Iovance
Biotherapeutics, Inc., Ultragenyx Pharmaceutical
Inc. and Kyowa Kirin Co., Ltd.
5Thank You!